Regulatory Affairs Management
Leading regulatory affairs managers can act as a seamless extension of Sponsor regulatory teams.
Thanks to MMS and especially the team… we reset the relationship that we have with the FDA and moved our lead asset forward through to getting our clinical trial started.
MMS regulatory strategy experts provide consulting and can be assigned as the product lead or a lead for a specific submission type, if needed.
MMS Regulatory Affairs Managers are a true extension of Sponsor regulatory affairs teams. These knowledgeable, experienced resources are assigned to specific products and applications and work with Sponsor teams to execute regulatory activities and facilitate optimal progress and development.
Our Regulatory Affairs Managers are responsible to support the following:
- Communication of regulatory requirements and provision of status updates to stakeholders in the Sponsor company
- Development of Module 1 content required for global health authority interactions, including the FDA, EMA, and others
- Review of required regulatory documentation and files created by other functional lines
- Representation to and interactions with global health authorities on behalf of the Sponsor
Leads the team in the preparation and execution of large and/or complex dossiers
For more information on submissions support, see here.
Regulatory Affairs Managers and Strategists regularly create regional, Module 1 documentation and provide the Sponsor team with expert guidance on the content and format needed to support key interactions with global health authorities.
Suggested For You
regulatory intelligence
January 17th, 2025
The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development
regulatory intelligence
January 17th, 2025
New FDA Protocol Deviation Guidance: Planning for the Things That Don’t Go According to Plan
perspectives
January 9th, 2025
How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA
perspectives
January 2nd, 2025
Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations
perspectives
December 17th, 2024
Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs
perspectives
December 11th, 2024
Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs
regulatory intelligence
December 4th, 2024
FDA Issues Detailed Guidance on Development of Gene Therapy Products
news
December 4th, 2024
AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium
perspectives
November 26th, 2024
Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs
perspectives
November 21st, 2024
Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success
news
November 19th, 2024
MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year
perspectives
November 12th, 2024
REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar